Physician profile
Stephen W Moore
NPI 1326087008
$1,501.84
in general payments reported to CMS, 2019-2025
28 companies · $20.28 in 2025
The $20.28 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $226 · 2021: $477 · 2022: $120 · 2023: $22.07 · 2024: $68.97 · 2025: $20.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $111.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $279.80 | 2019-2021 | |
| Abbott Laboratories | $136.09 | 2021-2023 | Freestyle Libre 2 |
| Abbvie INC. | $119.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $118.88 | 2019-2021 | |
| Amgen INC. | $115.41 | 2019-2021 | |
| Novo Nordisk INC | $67.50 | 2019-2021 | |
| Glaxosmithkline, LLC. | $64.33 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.74 | 2019-2021 | |
| Lilly USA, LLC | $48.42 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $46.01 | 2020-2021 | |
| Pfizer INC. | $42.06 | 2019-2024 | |
| Gilead Sciences, INC. | $40.52 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $36.89 | 2019-2021 | |
| Amarin Pharma, INC. | $36.02 | 2019-2021 | |
| Protega Pharmaceutials INC | $35.18 | 2024 | Roxybond |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $31.74 | 2019 | |
| Nestle Healthcare Nutrition INC. | $29.83 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.75 | 2019 | |
| Scilex Pharmaceuticals INC. | $28.74 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $20.28 | 2025 | Gvoke Hypopen |
| Esperion Therapeutics, INC. | $19.11 | 2021 | |
| Exact Sciences Corporation | $18.83 | 2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $15.90 | 2020 | |
| Eisai INC. | $15.26 | 2021 | |
| Seqirus USA INC | $13.28 | 2019 | |
| Phadia US INC. | $13.02 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.83 | 2019 | |
| Astellas Pharma US INC | $11.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.